What is Zacks Research’s Estimate for ESPR FY2027 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research decreased their FY2027 EPS estimates for shares of Esperion Therapeutics in a research report issued to clients and investors on Monday, July 28th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of $0.05 per share for the year, down from their previous estimate of $0.06. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). The business had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million. Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%.

Other research analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. The Goldman Sachs Group cut their target price on Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. Finally, Needham & Company LLC decreased their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Esperion Therapeutics Stock Down 7.5%

Esperion Therapeutics stock opened at $1.47 on Tuesday. The firm has a market cap of $291.35 million, a P/E ratio of -1.84 and a beta of 0.70. The business has a fifty day moving average of $1.12 and a two-hundred day moving average of $1.35. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $3.94.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wasatch Advisors LP boosted its holdings in Esperion Therapeutics by 4.9% in the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock worth $53,861,000 after acquiring an additional 1,136,245 shares in the last quarter. Two Sigma Advisers LP boosted its stake in Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after purchasing an additional 16,100 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock worth $6,862,000 after purchasing an additional 1,020,243 shares in the last quarter. Nuveen LLC purchased a new stake in Esperion Therapeutics during the 1st quarter worth approximately $4,446,000. Finally, JPMorgan Chase & Co. increased its stake in Esperion Therapeutics by 18.6% during the 4th quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company’s stock valued at $5,399,000 after purchasing an additional 385,099 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.